Skip to content

13F-HR filed by Lamond Capital Partners LLC

Lamond Capital Partners LLC filed this 13F-HR for the quarter ended 2015-09-30, filed 2015-11-09, with 10 holding rows worth $133,620,000.

Accession
0001542550-15-000005
Filed
2015-11-09
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2015

A holdings report, 10 entries on the cover page, a total value of $133,620,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $133,620,000 with VALUE read as thousands by filing date, 13F file number 028-15156. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Amgen Inc.031162100COM150,000$20,748,000thousands by filing datecall
Oracle Corporation68389X105COM500,000$18,060,000thousands by filing datecall
OCULAR THERAPEUTIX INC67576A100COM1,233,285$17,340,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM100,000$15,639,000thousands by filing date
Amgen Inc.031162100COM100,000$13,832,000thousands by filing date
AbbVie,Inc.00287Y109COM250,000$13,603,000thousands by filing datecall
GW PHARMACEUTICALS PLC36197T103ADS120,000$10,964,000thousands by filing date
BIOMARIN PHARMACEUTICAL INC09061G101COM100,000$10,532,000thousands by filing date
CYPRESS SEMICONDUCTOR CORP232806109COM1,100,000$9,372,000thousands by filing date
KITE PHARMA INC49803L109COM63,400$3,530,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001542550-15-000005this filing2015-11-09acceptance time not in the bulk data set